Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Digital Health Neurology Commercial

Akili Strikes $125m Digital Med Deal With Japanese Partner

  • News

Executive Summary

PureTech Health's Akili has announced a $125m partnership with Japanese pharmaceutical company Shionogi to commercialize two of its digital therapeutics in Japan and Taiwan.

You may also be interested in...



Kids, Time To Play Your Medicine: Akili Prepares Launch Of EndeavorRx Video Game For ADHD

After being first to receive FDA clearance for a prescription-only software to treat ADHD and raising total funding of $230m, Akili plans a US launch in 2022 while targeting other indications.

Kids, Time To Play Your Medicine: Akili Prepares Launch Of EndeavorRx Video Game For ADHD

After being first to receive FDA clearance for a prescription-only software to treat ADHD and raising total funding of $230m, Akili plans a US launch in 2022 while targeting other indications.

Expert Panel Discusses Trends In Digital Health Investment

An expert panel at the AdvaMed MedTech Conference in San Francisco discussed trends in digital health investment including market opportunities and regulatory and reimbursement challenges.

Table

View full table

Related Content

Medtech Insight

Topics

Related Companies

Tags:
Digital Health Neurology Commercial
Latest Headlines

NWW: Studies Back Nevro Pain Treatment, FTC Blesses Resonetics Nitinol Deal, Genetic Test Identifies Best RDN Patients

Getting Personal With Tom Miller: CEO Turned VC On Ethical Bets In Diagnostics

Postmarket Surveillance Continues To Challenge AI/ML Device Regulators

Q&A: Allyson Mullen On ‘Uncharted Waters’ Of Breakthrough Pathway

See All
UsernamePublicRestriction

Register

MT124760

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By